Brief: Kamada Provides provides Update On Phase 3 Clinical Trial Of Inhaled AAT

Kamada

07/11/2022 12:43

Nov 7 (Reuters) - Kamada Ltd  KMDA.TA :
    * KAMADA PROVIDES UPDATE ON RECENT PROGRESS ACHIEVED IN
ONGOING
PIVOTAL PHASE 3 CLINICAL TRIAL OF INHALED AAT
    * KAMADA LTD - TRIAL RECRUITMENT BEGINNING TO ACCELERATE; 30
PATIENTS ENROLLED AND TREATED TO DATE
    * KAMADA LTD - INDEPENDENT DATA SAFETY MONITORING BOARD
(DSMB)
RECOMMENDS STUDY CONTINUATION WITHOUT MODIFICATION FOR FOURTH
TIME SINCE STUDY INITIATION
    * KAMADA LTD - TRIAL INCLUSION CRITERIA REVISED TO ALSO
INCLUDE
PATIENTS WITH SEVERE AIRFLOW LIMITATION
    * KAMADA LTD - INTENDS TO MEET WITH U.S. FDA AND EMA DURING
H1
2023 TO DISCUSS STUDY PROGRESS AND POTENTIAL OPPORTUNITIES TO
SHORTEN REGULATORY PATHWAY

Source text for Eikon:  ID:nGNX4fV33c 
Further company coverage:  KMDA.TA 
 ((Reuters.Briefs@thomsonreuters.com;))